Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Consensus Target Price from Analysts

Immunic, Inc. (NASDAQ:IMUX) has received a consensus rating of “Buy” from the nine brokerages that are presently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $12.67.

IMUX has been the topic of a number of analyst reports. William Blair began coverage on Immunic in a research note on Tuesday, March 25th. They issued an “outperform” rating on the stock. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Immunic in a research note on Friday, February 21st. D. Boral Capital reiterated a “buy” rating and issued a $17.00 price target on shares of Immunic in a research note on Tuesday. Finally, StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research report on Thursday, March 20th.

Institutional Trading of Immunic

Institutional investors and hedge funds have recently bought and sold shares of the business. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Immunic by 90.0% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company’s stock worth $205,000 after purchasing an additional 96,894 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Immunic by 480.6% during the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock worth $580,000 after buying an additional 479,846 shares during the last quarter. Focus Partners Wealth increased its position in Immunic by 1.1% in the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock valued at $2,168,000 after acquiring an additional 23,610 shares during the period. Bridgeway Capital Management LLC raised its stake in Immunic by 11.5% during the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock valued at $215,000 after acquiring an additional 22,200 shares during the last quarter. Finally, 683 Capital Management LLC lifted its position in Immunic by 2.2% during the 4th quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock worth $700,000 after acquiring an additional 15,349 shares during the period. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Stock Down 2.3 %

NASDAQ IMUX opened at $1.07 on Friday. Immunic has a 52 week low of $0.92 and a 52 week high of $2.11. The firm has a 50 day moving average of $1.09 and a two-hundred day moving average of $1.20. The stock has a market capitalization of $95.93 million, a PE ratio of -0.87 and a beta of 1.89.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.